Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

Summary

This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions. Metformin is a drug approved for the treatment of diabetes, but studies have shown that it may have some anticancer properties. Giving metformin may help prevent or slow the development of oral cancer from precancerous lesions.

Timeline

Start

2022-05-04

Primary completion

2024-03-16

Completion

2024-03-16

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications